Swissmedic has released guidance for Marketing Authorization Holders (MAHs) on electronically transmitting Individual Case Safety Reports (ICSRs) in E2B(R3) format via a Business-to-Business (B2B) gateway.

Key Points:

  • Technical Requirements: Outlines requirements and processes for E2B(R3) transmission, transitioning from E2B(R2).
  • Scope: Covers post-authorization ICSRs for medicinal products and therapeutic biologicals in Switzerland.
  • Compliance: Addresses deviations from EMA business rules, handling duplicates, and literature monitoring.
  • Mandatory Transmission: Emphasizes the required electronic submission of ICSRs, including specific types, attachments, and media types.
  • Data Elements: Discusses nullflavor flags, import/export processes, and references international standards (ISO, ICH, EMA).

This guide ensures compliance with the Swissmedic drug safety system and standardizes ICSR transmission.

Source: https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/mu/mu101_20_832_mb_guidance_for_industry_e2b_r3_gateway.pdf.download.pdf/MU101_20_832e_MB_Guidance_for_Industry_on_the_electronic_exchange_of_ICSRs_in_E2B(R3)_format_through_B2B_gateway.pdf

Region: Switzerland

pattern
pattern
Got questions? We’ve got answers!

Let's talk Regulatory!

Reach out to us and let’s unravel your Regulatory puzzle together. Unlock regulatory solutions with our global subject matter experts and tap into a wealth of regulatory intelligence.

Speak to an Expert